Meeting
2018 Genitourinary Cancers Symposium
EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.
Authors
Christopher J. Hoimes
University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH
Christopher J. Hoimes , Daniel Peter Petrylak , Thomas W. Flaig , Anne-Sophie Carret , Amal Melhem-Bertrandt , Jonathan E. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03288545
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS532)
DOI
10.1200/JCO.2018.36.6_suppl.TPS532
Abstract #
TPS532
Poster Bd #
N10
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
First Author: Christopher J. Hoimes
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
First Author: Peter H. O'Donnell
Poster
2020 ASCO Virtual Scientific Program
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
First Author: Nataliya Mar